-
Zhang R, Khare P, Banerjee P, Ivan C, Schneider S, Barbaglio F, Clise-Dwyer K, Jensen VB, Thompson E, Mendoza M, Chiorazzi N, Chen SS, Yan XJ, Jain N, Ghia P, Caligaris-Cappio F, Mendonsa R, Kasimsetty S, Swoboda R, Bayraktar R, Wierda W, Gandhi V, Calin GA, Keating MJ, Bertilaccio MTS. The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia. Blood Cancer J. 2024 Oct 23; 14(1):168.
PMID: 39438453; PMCID: PMC11496494.
Citations: Fields:
Translation:
HumansAnimals
-
Aslan B, Manyam G, Iles LR, Tantawy SI, Desikan SP, Wierda WG, Gandhi V, Aslan B, Manyam G, Iles LR, Tantawy SI, Desikan SP, Wierda WG, Gandhi V. Transcriptomic and proteomic differences in BTK-WT and BTK-mutated CLL and their changes during therapy with pirtobrutinib. Blood Adv. 2024 Sep 10; 8(17):4487-4501.
PMID: 38968154; PMCID: PMC11395759.
Citations: Fields:
Translation:
HumansCells
-
Perez-Oquendo M, Romano G, Farris DP, Gandhi V, Wistuba II, Tillman RE, Udan R, Mangahas P, Soundararajan R. A structured curriculum supporting biomedical trainees' transition into independent academic positions and early career success. BMC Med Educ. 2024 Apr 08; 24(1):379.
PMID: 38589919; PMCID: PMC11000405.
Citations: Fields:
Translation:
Humans
-
Sexauer AN, Alexe G, Gustafsson K, Zanetakos E, Milosevic J, Ayres M, Gandhi V, Pikman Y, Stegmaier K, Sykes DB. DHODH: a promising target in the treatment of T-cell acute lymphoblastic leukemia. Blood Adv. 2023 11 14; 7(21):6685-6701.
PMID: 37648673; PMCID: PMC10641474.
Citations: Fields:
Translation:
HumansAnimalsCells
-
Pullarkat V, Chen LS, Palmer J, Zhang J, Synold TW, Buettner R, Truong Nguyen LX, Marcucci G, Tsai NC, Wang Y, O'Hearn J, Gandhi V, Rosen ST. A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics. Cancer. 2024 03 01; 130(5):727-739.
PMID: 37897709.
Citations: Fields:
Translation:
HumansCTClinical Trials
-
Tantawy SI, Timofeeva N, Sarkar A, Gandhi V. Targeting MCL-1 protein to treat cancer: opportunities and challenges. Front Oncol. 2023; 13:1226289.
PMID: 37601693; PMCID: PMC10436212.
-
Tantawy SI, Timofeeva N, Hernandez A, Sarkar A, Gandhi V. Decoding the mechanism behind MCL-1 inhibitors: A pathway to understanding MCL-1 protein stability. Oncotarget. 2023 06 21; 14:653-655.
PMID: 37343064; PMCID: PMC10284423.
Citations:
1 Fields:
Translation:
HumansCells
-
Timofeeva N, Ayres ML, Baran N, Santiago-O'Farrill JM, Bildik G, Lu Z, Konopleva M, Gandhi V. Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia. Front Oncol. 2023; 13:1161254.
PMID: 37228498; PMCID: PMC10203524.
-
Aslan B, Tantawy SI, Gandhi V. Curing CLL: one clone at a time. Blood Adv. 2023 05 09; 7(9):1926-1928.
PMID: 36355806; PMCID: PMC10202734.
Citations: Fields:
Translation:
HumansCells
-
Tantawy SI, Sarkar A, Hubner S, Tan Z, Wierda WG, Eldeib A, Zhang S, Kornblau S, Gandhi V. Mechanisms of MCL-1 Protein Stability Induced by MCL-1 Antagonists in B-Cell Malignancies. Clin Cancer Res. 2023 01 17; 29(2):446-457.
PMID: 36346691; PMCID: PMC9852224.
Citations:
3 Fields:
Translation:
HumansCells
-
Boddu PC, Senapati J, Ravandi-Kashani F, Jabbour EJ, Jain N, Ayres M, Chen Y, Keating MJ, Kantarjian HM, Gandhi V, Kadia TM. A phase 1 study to evaluate the safety, pharmacology, and feasibility of continuous infusion nelarabine in patients with relapsed and/or refractory lymphoid malignancies. Cancer. 2023 02 15; 129(4):580-589.
PMID: 36448227.
Citations: Fields:
Translation:
HumansCTClinical Trials
-
Demarest JF, Kienle M, Boytz R, Ayres M, Kim EJ, Patten JJ, Chung D, Gandhi V, Davey RA, Sykes DB, Shohdy N, Pottage JC, Kumar VS. Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19. Antiviral Res. 2022 10; 206:105403.
PMID: 36041646; PMCID: PMC9420051.
Citations:
-
Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, Gagea M, Bertilaccio MTS, Wierda WG, Gandhi V. Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia. Blood Cancer J. 2022 05 20; 12(5):80.
PMID: 35595730; PMCID: PMC9123190.
Citations: Fields:
Translation:
HumansAnimalsCells
-
Hoang DH, Morales C, Rodriguez IR, Valerio M, Guo J, Chen MH, Wu X, Horne D, Gandhi V, Chen LS, Zhang B, Pullarkat V, Rosen ST, Marcucci G, Buettner R, Nguyen LXT. Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism. Cancers (Basel). 2022 Mar 11; 14(6).
PMID: 35326597; PMCID: PMC8946614.
Citations:
-
Zhang R, Banerjee P, Galletti G, McManus S, Mazza M, Nicolini F, Martinelli G, Ivan C, Veliz Rodriguez T, Barbaglio F, Wierda W, Gandhi V, Keating M, Caligaris-Cappio F, Ghia P, Bertilaccio MTS, Tettamanti S, Rotiroti MC, Giordano Attianese GMP, Arcangeli S, Scarf? L, Ponzoni M, Biondi A, Biagi E. Lenalidomide enhances CD23.CAR T cell therapy in chronic lymphocytic leukemia. Leuk Lymphoma. 2022 07; 63(7):1566-1579.
PMID: 35259043; PMCID: PMC9828187.
Citations:
2 Fields:
Translation:
HumansCells
-
Teakell S, Chen LS, Stellrecht CM, Gandhi V. The role of p53 and p21 on 8-chloro-adenosine-induced cellular response. Nucleosides Nucleotides Nucleic Acids. 2022; 41(12):1359-1374.
PMID: 35227162.
-
Yi X, Jain N, Iles LR, Ayres ML, Wierda WG, Gandhi V. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia. Front Oncol. 2022; 12:833714.
PMID: 35273915; PMCID: PMC8901605.
Citations:
-
Aslan B, Hubner SE, Fox JA, Taverna P, Wierda WG, Kornblau SM, Gandhi V. Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase. Haematologica. 2022 01 01; 107(1):292-297.
PMID: 34498444; PMCID: PMC8719067.
Citations:
2 Fields:
Translation:
HumansCells
-
Galan-Cobo A, Stellrecht CM, Yilmaz E, Yang C, Qian Y, Qu X, Akhter I, Ayres ML, Fan Y, Tong P, Diao L, Ding J, Giri U, Gudikote J, Nilsson M, Wierda WG, Wang J, Skoulidis F, Minna JD, Gandhi V, Heymach JV. Enhanced Vulnerability of LKB1-Deficient NSCLC to Disruption of ATP Pools and Redox Homeostasis by 8-Cl-Ado. Mol Cancer Res. 2022 02; 20(2):280-292.
PMID: 34654720; PMCID: PMC8816854.
Citations:
2 Fields:
Translation:
HumansCells
-
Aslan B, Kismali G, Chen LS, Iles LR, Mahendra M, Peoples M, Gagea M, Fowlkes NW, Zheng X, Wang J, Vellano CP, Marszalek JR, Bertilaccio MTS, Gandhi V. Development and characterization of prototypes for in?vitro and in?vivo mouse models of ibrutinib-resistant CLL. Blood Adv. 2021 08 24; 5(16):3134-3146.
PMID: 34424317; PMCID: PMC8405195.
Citations:
2 Fields:
Translation:
HumansAnimals
-
Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, Takahashi K, Estrov Z, Sasaki K, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang SA, Garg N, Wang X, Wei C, Cruz N, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda WG. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial. JAMA Oncol. 2021 Aug 01; 7(8):1213-1219.
PMID: 34110383; PMCID: PMC8193546.
Citations:
8 Fields:
Translation:
HumansCTClinical Trials
-
Sarkar A, Gandhi V. Correction to: Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies. Mol Cell Biochem. 2021 Jul; 476(7):2887.
PMID: 34021870.
-
Jain N, Thompson P, Burger J, Ferrajoli A, Takahashi K, Estrov Z, Borthakur G, Bose P, Kadia T, Pemmaraju N, Sasaki K, Konopleva M, Jabbour E, Garg N, Wang X, Kanagal-Shamanna R, Patel K, Wang W, Jorgensen J, Wang S, Lopez W, Ayala A, Plunkett W, Gandhi V, Kantarjian H, O'Brien S, Keating M, Wierda WG. Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia. 2021 12; 35(12):3421-3429.
PMID: 34007049.
Citations:
3 Fields:
Translation:
HumansCellsCTClinical Trials
-
Timofeeva N, Gandhi V. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Blood Cancer J. 2021 04 29; 11(4):79.
PMID: 33927183; PMCID: PMC8085243.
Citations:
7 Fields:
Translation:
HumansAnimals
-
Buettner R, Nguyen LXT, Morales C, Chen MH, Wu X, Chen LS, Hoang DH, Hernandez Vargas S, Pullarkat V, Gandhi V, Marcucci G, Rosen ST. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine. J Hematol Oncol. 2021 04 26; 14(1):70.
PMID: 33902674; PMCID: PMC8074444.
Citations:
6 Fields:
Translation:
HumansAnimalsCells
-
Groenland SL, Ratain MJ, Chen LS, Gandhi V. The Right Dose: From Phase I to Clinical Practice. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:92-106.
PMID: 34010057.
Citations: Fields:
Translation:
Humans
-
Bose P, Gandhi V. Managing chronic lymphocytic leukemia in 2020: an update on recent clinical advances with a focus on BTK and BCL-2 inhibitors. Fac Rev. 2021; 10:22.
PMID: 33718939; PMCID: PMC7946394.
Citations:
-
Sarkar A, Stellrecht CM, Vangapandu HV, Ayres M, Kaipparettu BA, Park JH, Balakrishnan K, Burks JK, Pandita TK, Hittelman WN, Neelapu SS, Gandhi V. Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica. 2021 02 01; 106(2):495-512.
PMID: 32029507; PMCID: PMC7849759.
Citations:
7 Fields:
Translation:
HumansAnimalsCells
-
Timofeeva N, Gandhi V. Metabolism meets apoptosis in AML. Leuk Lymphoma. 2021 03; 62(3):514-516.
PMID: 33356786.
Citations: Fields:
Translation:
Humans
-
Sarkar A, Gandhi V. Activation of ATM kinase by ROS generated during ionophore-induced mitophagy in human T and B cell malignancies. Mol Cell Biochem. 2021 Jan; 476(1):417-423.
PMID: 32996079; PMCID: PMC7867566.
Citations:
6 Fields:
Translation:
HumansAnimalsCells
-
Yi X, Sarkar A, Kismali G, Aslan B, Ayres M, Iles LR, Keating MJ, Wierda WG, Long JP, Bertilaccio MTS, Gandhi V. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2020 07 15; 26(14):3856-3867.
PMID: 31937611; PMCID: PMC7358119.
Citations:
21 Fields:
Translation:
HumansCells
-
Banerjee P, Zhang R, Ivan C, Galletti G, Clise-Dwyer K, Barbaglio F, Aracil M, Klein C, Wierda W, Plunkett W, Caligaris-Cappio F, Gandhi V, Keating MJ, Bertilaccio MTS, Scarf? L. Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia. Cancer Immunol Res. 2019 12; 7(12):2036-2051.
PMID: 31530560; PMCID: PMC6891195.
Citations:
20 Fields:
Translation:
HumansAnimalsCells
-
Jain N, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. Reply. N Engl J Med. 2019 08 22; 381(8):789.
PMID: 31433937.
Citations:
2 Fields:
Translation:
Humans
-
Chen LS, Keating MJ, Wierda WG, Gandhi V. Induction of apoptosis by MCL-1 inhibitors in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2019 12; 60(12):3063-3066.
PMID: 31161836.
Citations:
2 Fields:
Translation:
Humans
-
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G, Takahashi K, Estrov Z, Fowler N, Kadia T, Konopleva M, Alvarado Y, Yilmaz M, DiNardo C, Bose P, Ohanian M, Pemmaraju N, Jabbour E, Sasaki K, Kanagal-Shamanna R, Patel K, Jorgensen J, Garg N, Wang X, Sondermann K, Cruz N, Wei C, Ayala A, Plunkett W, Kantarjian H, Gandhi V, Wierda W. Ibrutinib and Venetoclax for First-Line Treatment of CLL. N Engl J Med. 2019 05 30; 380(22):2095-2103.
PMID: 31141631.
Citations:
139 Fields:
Translation:
HumansCTClinical Trials
-
Galan-Cobo A, Sitthideatphaiboon P, Qu X, Poteete A, Pisegna MA, Tong P, Chen PH, Boroughs LK, Rodriguez MLM, Zhang W, Parlati F, Wang J, Gandhi V, Skoulidis F, DeBerardinis RJ, Minna JD, Heymach JV. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in KRAS-Mutant Lung Adenocarcinoma. Cancer Res. 2019 07 01; 79(13):3251-3267.
PMID: 31040157; PMCID: PMC6606351.
Citations:
78 Fields:
Translation:
HumansAnimalsCells
-
Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V. PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells. Oncotarget. 2019 Apr 19; 10(29):2793-2809.
PMID: 31073371; PMCID: PMC6497463.
-
Buettner R, Nguyen LXT, Kumar B, Morales C, Liu C, Chen LS, Pemovska T, Synold TW, Palmer J, Thompson R, Li L, Hoang DH, Zhang B, Ghoda L, Kowolik C, Kontro M, Leitch C, Wennerberg K, Yu X, Chen CC, Horne D, Gandhi V, Pullarkat V, Marcucci G, Rosen ST. 8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia. J Cell Physiol. 2019 Sep; 234(9):16295-16303.
PMID: 30770553; PMCID: PMC6697246.
-
Bose P, Chen LS, Gandhi V. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia - learning from the 'real world'. Leuk Lymphoma. 2019 07; 60(7):1603-1605.
PMID: 30724681.
Citations:
1 Fields:
Translation:
Humans
-
Aslan B, Ayres ML, Gandhi V. Ex Vivo Pharmacological Profiling in Chronic Lymphocytic Leukemia Cells. Methods Mol Biol. 2019; 1881:19-25.
PMID: 30350194.
Citations: Fields:
Translation:
HumansCells
-
Bertilaccio MTS, Zhang R, Banerjee P, Gandhi V. In Vitro Assay to Study CLL and Monocyte Interactions. Methods Mol Biol. 2019; 1881:113-119.
PMID: 30350201.
Citations:
1 Fields:
Translation:
HumansCells
-
Vangapandu HV, Gandhi V. Extracellular Flux Assays to Determine Oxidative Phosphorylation and Glycolysis in Chronic Lymphocytic Leukemia Cells. Methods Mol Biol. 2019; 1881:121-128.
PMID: 30350202.
Citations:
3 Fields:
Translation:
HumansCells
-
Chen W, Fan H, Balakrishnan K, Wang Y, Sun H, Fan Y, Gandhi V, Arnold LA, Peng X. Discovery and Optimization of Novel Hydrogen Peroxide Activated Aromatic Nitrogen Mustard Derivatives as Highly Potent Anticancer Agents. J Med Chem. 2018 10 25; 61(20):9132-9145.
PMID: 30247905.
Citations:
10 Fields:
Translation:
HumansCells
-
Chen LS, Bose P, Cruz ND, Jiang Y, Wu Q, Thompson PA, Feng S, Kroll MH, Qiao W, Huang X, Jain N, Wierda WG, Keating MJ, Gandhi V. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia. Blood. 2018 11 22; 132(21):2249-2259.
PMID: 30254130; PMCID: PMC6251009.
Citations:
29 Fields:
Translation:
HumansCellsCTClinical Trials
-
Elsayed AH, Cao X, Crews KR, Gandhi V, Plunkett W, Rubnitz JE, Ribeiro RC, Pounds SB, Lamba JK. Comprehensive Ara-C SNP score predicts leukemic cell intracellular ara-CTP levels in pediatric acute myeloid leukemia patients. Pharmacogenomics. 2018 09 01; 19(14):1101-1110.
PMID: 30088438; PMCID: PMC6219441.
Citations:
2 Fields:
Translation:
Humans
-
Abou Dalle I, Cortes JE, Pinnamaneni P, Lamothe B, Diaz Duque A, Randhawa J, Pemmaraju N, Jabbour E, Ferrajoli A, Wierda WG, Estrov Z, Konopleva M, Ravandi F, Alvarado Y, Borthakur G, Gandhi V, Kantarjian HM. A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
PMID: 30071517.
Citations:
5 Fields:
Translation:
HumansCTClinical Trials
-
Vangapandu HV, Alston B, Morse J, Ayres ML, Wierda WG, Keating MJ, Marszalek JR, Gandhi V. Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells. Oncotarget. 2018 May 18; 9(38):24980-24991.
PMID: 29861847; PMCID: PMC5982765.
-
Cortes J, Tamura K, DeAngelo DJ, de Bono J, Lorente D, Minden M, Uy GL, Kantarjian H, Chen LS, Gandhi V, Godin R, Keating K, McEachern K, Vishwanathan K, Pease JE, Dean E. Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. Br J Cancer. 2018 05; 118(11):1425-1433.
PMID: 29765150; PMCID: PMC5988656.
Citations:
23 Fields:
Translation:
HumansCellsCTClinical Trials
-
Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, Ivan C, Morse J, Nelson M, Keating MJ, Wierda WG, Marszalek JR, Gandhi V. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018 04; 32(4):920-930.
PMID: 29099493; PMCID: PMC5871548.
Citations:
16 Fields:
Translation:
HumansAnimalsCells
-
Bose P, Gandhi V. Recent therapeutic advances in chronic lymphocytic leukemia. F1000Res. 2017; 6:1924.
PMID: 29152232; PMCID: PMC5664994.
-
Vangapandu HV, Chen H, Wierda WG, Keating MJ, Korkut A, Gandhi V. Proteomics profiling identifies induction of caveolin-1 in chronic lymphocytic leukemia cells by bone marrow stromal cells. Leuk Lymphoma. 2018 06; 59(6):1427-1438.
PMID: 28971726; PMCID: PMC5882591.
Citations:
4 Fields:
Translation:
HumansCells
-
Vangapandu HV, Ayres ML, Bristow CA, Wierda WG, Keating MJ, Balakrishnan K, Stellrecht CM, Gandhi V. The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells. Neoplasia. 2017 Oct; 19(10):762-771.
PMID: 28863345; PMCID: PMC5577399.
Citations:
12 Fields:
Translation:
HumansCells
-
Citations:
18 Fields:
Translation:
HumansCells
-
Stellrecht CM, Chen LS, Ayres ML, Dennison JB, Shentu S, Chen Y, Keating MJ, Wierda WG, Gandhi V. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol. 2017 10; 179(2):266-271.
PMID: 28737232; PMCID: PMC5638689.
Citations:
10 Fields:
Translation:
HumansCells
-
Short NJ, Kantarjian H, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Jabbour E. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2018 04; 59(4):813-820.
PMID: 28718728; PMCID: PMC5773400.
Citations:
7 Fields:
Translation:
HumansCTClinical Trials
-
Jabbour E, Short NJ, Ravandi F, Huang X, Xiao L, Garcia-Manero G, Plunkett W, Gandhi V, Sasaki K, Pemmaraju N, Daver NG, Borthakur G, Jain N, Konopleva M, Estrov Z, Kadia TM, Wierda WG, DiNardo CD, Brandt M, O'Brien SM, Cortes JE, Kantarjian H. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia. Cancer. 2017 Nov 15; 123(22):4430-4439.
PMID: 28708931; PMCID: PMC5739034.
Citations:
15 Fields:
Translation:
HumansCTClinical Trials
-
Yang Q, Modi P, Korkut A, Fernandes SM, Hanna J, Brown JR, Gandhi V. Changes in Bcl-2 Family Protein Profile During Idelalisib Therapy Mimic Those During Duvelisib Therapy in Chronic Lymphocytic Leukemia Lymphocytes. JCO Precis Oncol. 2017; 1.
PMID: 32913964; PMCID: PMC7446340.
-
Vangapandu HV, Jain N, Gandhi V. Duvelisib: a phosphoinositide-3 kinase d/? inhibitor for chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2017 May; 26(5):625-632.
PMID: 28388280; PMCID: PMC5584596.
Citations:
21 Fields:
Translation:
HumansAnimals
-
Jain N, Balakrishnan K, Ferrajoli A, O'Brien SM, Burger JA, Kadia TM, Cortes JE, Ayres ML, Tambaro FP, Keating MJ, Gandhi V, Wierda WG. A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL. Oncotarget. 2017 Mar 28; 8(13):22104-22112.
PMID: 27655665; PMCID: PMC5400650.
Citations:
3 Fields:
Translation:
HumansCTClinical Trials
-
Wang Y, Fan H, Balakrishnan K, Lin Z, Cao S, Chen W, Fan Y, Guthrie QA, Sun H, Teske KA, Gandhi V, Arnold LA, Peng X. Hydrogen peroxide activated quinone methide precursors with enhanced DNA cross-linking capability and cytotoxicity towards cancer cells. Eur J Med Chem. 2017 Jun 16; 133:197-207.
PMID: 28388522; PMCID: PMC5652303.
Citations:
6 Fields:
Translation:
HumansCells
-
Baljevic M, Zaman S, Baladandayuthapani V, Lin YH, de Partovi CM, Berkova Z, Amini B, Thomas SK, Shah JJ, Weber DM, Fu M, Cleeland CS, Wang XS, Stellrecht CM, Davis RE, Gandhi V, Orlowski RZ. Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma. Ann Hematol. 2017 Jun; 96(6):977-985.
PMID: 28337527; PMCID: PMC5406425.
Citations:
7 Fields:
Translation:
HumansCTClinical Trials
-
Modi P, Balakrishnan K, Yang Q, Wierda WG, Keating MJ, Gandhi V. Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. 2017 Mar 07; 8(10):16259-16274.
PMID: 28187444; PMCID: PMC5369961.
Citations:
6 Fields:
Translation:
HumansAnimalsCells
-
Citations:
69 Fields:
Translation:
HumansAnimals
-
Gandhi V, Jalali R. A Conference of New Ideas in Cancer-Challenging Dogmas. Cancer Res. 2017 01 15; 77(2):234-237.
PMID: 28062401.
Citations: Fields:
Translation:
Humans
-
Patel V, Balakrishnan K, Bibikova E, Ayres M, Keating MJ, Wierda WG, Gandhi V. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells. Clin Cancer Res. 2017 Jul 15; 23(14):3734-3743.
PMID: 28034907; PMCID: PMC5491371.
Citations:
45 Fields:
Translation:
HumansCells
-
Patel VM, Balakrishnan K, Douglas M, Tibbitts T, Xu EY, Kutok JL, Ayers M, Sarkar A, Guerrieri R, Wierda WG, O'Brien S, Jain N, Stern HM, Gandhi V. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia. 2017 09; 31(9):1872-1881.
PMID: 28017967; PMCID: PMC5540815.
Citations:
30 Fields:
Translation:
HumansCellsCTClinical Trials
-
Kadia TM, Gandhi V. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Rev Hematol. 2017 Jan; 10(1):1-8.
PMID: 27869523; PMCID: PMC5578611.
Citations:
10 Fields:
Translation:
HumansAnimals
-
Mendes VIS, Bartholomeusz GA, Ayres M, Gandhi V, Salvador JAR. Corrigendum to "Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells" [Eur. J. Med. Chem. 123 (2016) 317-331]. Eur J Med Chem. 2016 11 29; 124:1004-1005.
PMID: 27783971; PMCID: PMC5654515.
-
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2016 10 13; 9(1):110.
PMID: 27737688; PMCID: PMC5064904.
-
Bose P, Gandhi VV, Keating MJ. Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia: rationale for lower doses. Expert Opin Drug Metab Toxicol. 2016 Nov; 12(11):1381-1392.
PMID: 27686109; PMCID: PMC5391303.
-
Patel P, Vora H, Aggarwal BB, Gandhi V, Mehta K, Pathak S. Prevention and Treatment of Cancer: Hypes and Hopes 6th International Translational Cancer Research Conference. Anticancer Res. 2016 09; 36(9):4971-5.
PMID: 27630358.
Citations: Fields:
Translation:
Humans
-
Mendes VIS, Bartholomeusz GA, Ayres M, Gandhi V, Salvador JAR. Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells. Eur J Med Chem. 2016 Nov 10; 123:317-331.
PMID: 27484517; PMCID: PMC5652311.
Citations:
12 Fields:
Translation:
HumansCells
-
Balakrishnan K, Fu M, Onida F, Wierda WG, Keating MJ, Gandhi V. Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic. Oncotarget. 2016 Jun 28; 7(26):39458-39472.
PMID: 27223062; PMCID: PMC5129945.
Citations:
5 Fields:
Translation:
HumansAnimalsCells
-
Yang Q, Chen LS, Ha MJ, Do KA, Neelapu SS, Gandhi V. Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res. 2017 Jan 01; 23(1):181-192.
PMID: 27342398; PMCID: PMC5433851.
Citations:
8 Fields:
Translation:
HumansAnimalsCells
-
Chen LS, Yang JY, Liang H, Cortes JE, Gandhi V. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leuk Lymphoma. 2016 12; 57(12):2863-2873.
PMID: 27054578; PMCID: PMC5650058.
Citations:
9 Fields:
Translation:
HumansCells
-
Lamothe B, Wierda WG, Keating MJ, Gandhi V. Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses. Clin Cancer Res. 2016 Sep 15; 22(18):4712-26.
PMID: 27026200; PMCID: PMC5118040.
Citations:
12 Fields:
Translation:
HumansCells
-
Citations:
3 Fields:
Translation:
HumansAnimalsCells
-
Patel V, Keating MJ, Wierda WG, Gandhi V. Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. Leuk Lymphoma. 2016; 57(6):1494-7.
PMID: 26440741; PMCID: PMC4963009.
Citations:
9 Fields:
Translation:
HumansCells
-
Cervantes-Gomez F, Lavergne B, Keating MJ, Wierda WG, Gandhi V. Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2016 Feb; 57(2):436-444.
PMID: 26088877; PMCID: PMC4814351.
-
Kearney AY, Fan YH, Giri U, Saigal B, Gandhi V, Heymach JV, Zurita AJ. 8-Chloroadenosine Sensitivity in Renal Cell Carcinoma Is Associated with AMPK Activation and mTOR Pathway Inhibition. PLoS One. 2015; 10(8):e0135962.
PMID: 26313261; PMCID: PMC4552467.
Citations:
6 Fields:
Translation:
HumansCells
-
Zaman S, Wang R, Gandhi V. Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells. Exp Hematol. 2015 Nov; 43(11):951-962.e3.
PMID: 26257207; PMCID: PMC4630139.
Citations:
6 Fields:
Translation:
HumansCells
-
Wang J, Yin H, Panandikar A, Gandhi V, Sen S. Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. Int J Oncol. 2015 Aug; 47(2):782-90.
PMID: 26058363; PMCID: PMC4501665.
Citations:
1 Fields:
Translation:
HumansAnimalsCells
-
Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V. The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL. Leukemia. 2015 Sep; 29(9):1811-22.
PMID: 25917267; PMCID: PMC4558374.
Citations:
75 Fields:
Translation:
HumansCells
-
Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2015 Aug 15; 21(16):3705-15.
PMID: 25829398; PMCID: PMC4537801.
Citations:
91 Fields:
Translation:
HumansCells
-
Zaman S, Shentu S, Yang J, He J, Orlowski RZ, Stellrecht CM, Gandhi V. Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells. Neoplasia. 2015 Mar; 17(3):289-300.
PMID: 25810013; PMCID: PMC4372650.
Citations:
11 Fields:
Translation:
HumansAnimalsCells
-
Yang Q, Modi P, Newcomb T, Gandhi V, Qu?va C. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma. Clin Cancer Res. 2015 Apr 01; 21(7):1537-42.
PMID: 25670221; PMCID: PMC4523214.
Citations:
77 Fields:
Translation:
Humans
-
Lamothe B, Cervantes-Gomez F, Sivina M, Wierda WG, Keating MJ, Gandhi V. Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia. Blood. 2015 Jan 08; 125(2):407-10.
PMID: 25573971; PMCID: PMC4287645.
Citations:
13 Fields:
Translation:
HumansCells
-
Patel V, Balakrishnan K, Keating MJ, Wierda WG, Gandhi V. Expression of executioner procaspases and their activation by a procaspase-activating compound in chronic lymphocytic leukemia cells. Blood. 2015 Feb 12; 125(7):1126-36.
PMID: 25538042; PMCID: PMC4326772.
Citations:
17 Fields:
Translation:
HumansAnimalsCells
-
Balakrishnan K, Burger JA, Fu M, Doifode T, Wierda WG, Gandhi V. Regulation of Mcl-1 expression in context to bone marrow stromal microenvironment in chronic lymphocytic leukemia. Neoplasia. 2014 Dec; 16(12):1036-46.
PMID: 25499217; PMCID: PMC4309260.
Citations:
20 Fields:
Translation:
HumansCells
-
Mehta K, Gandhi V, Pathak S, Aggarwal BB, Grover RK. Multi-targeted approach to cancer treatment: an international translational cancer research symposium. Anticancer Res. 2014 Nov; 34(11):6791-5.
PMID: 25368293.
Citations:
4 Fields:
Translation:
HumansCells
-
Chen LS, Keating MJ, Gandhi V. Blood collection methods affect cellular protein integrity: implications for clinical trial biomarkers and ZAP-70 in CLL. Blood. 2014 Aug 14; 124(7):1192-5.
PMID: 25124785; PMCID: PMC4133491.
Citations:
2 Fields:
Translation:
Humans
-
Chen W, Balakrishnan K, Kuang Y, Han Y, Fu M, Gandhi V, Peng X. Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes. J Med Chem. 2014 Jun 12; 57(11):4498-510.
PMID: 24801734; PMCID: PMC4133937.
Citations:
23 Fields:
Translation:
HumansCells
-
Citations:
13 Fields:
Translation:
HumansCells
-
Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 01; 20(7):1735-40.
PMID: 24501394; PMCID: PMC4048124.
Citations:
43 Fields:
Translation:
HumansCells
-
Zaman S, Wang R, Gandhi V. Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma. 2014 Sep; 55(9):1980-92.
PMID: 24295132; PMCID: PMC4152229.
Citations:
61 Fields:
Translation:
HumansAnimalsCells
-
Yang Q, Chen LS, Gandhi V. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments. Curr Pharm Des. 2014; 20(42):6670-81.
PMID: 25341939.
Citations:
1 Fields:
Translation:
HumansAnimals
-
Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):231-8.
PMID: 24440659; PMCID: PMC4182922.
Citations:
5 Fields:
Translation:
HumansCTClinical Trials
-
Phillip CJ, Zaman S, Shentu S, Balakrishnan K, Zhang J, Baladandayuthapani V, Taverna P, Redkar S, Wang M, Stellrecht CM, Gandhi V. Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines. J Hematol Oncol. 2013 Dec 10; 6:92.
PMID: 24326130; PMCID: PMC3878866.
Citations:
11 Fields:
Translation:
HumansCells
-
Balakrishnan K, Gandhi V. Uncoupling endoplasmic reticulum stress and autophagy: a potential implication for chronic lymphocytic leukemia therapy. Leuk Lymphoma. 2013 Dec; 54(12):2581-3.
PMID: 23656199.
Citations: Fields:
Translation:
Humans
-
Gandhi V. A new feature in Leukemia & Lymphoma: "Emerging drug profile". Leuk Lymphoma. 2013 Oct; 54(10):2131-2.
PMID: 24041378.
Citations: Fields:
Translation:
Humans
-
Citations:
14 Fields:
Translation:
HumansCells
-
Cao X, Mitra AK, Pounds S, Crews KR, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients. Pharmacogenomics. 2013 Sep; 14(12):1449-66.
PMID: 24024897; PMCID: PMC3860742.
Citations:
17 Fields:
Translation:
HumansCells
-
Yang Q, Chen LS, Neelapu SS, Gandhi V. Combination of Pim kinase inhibitor SGI-1776 and bendamustine in B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S355-62.
PMID: 24290221; PMCID: PMC3951504.
Citations:
9 Fields:
Translation:
HumansCells
-
Cervantes-Gomez F, Chen LS, Orlowski RZ, Gandhi V. Biological effects of the Pim kinase inhibitor, SGI-1776, in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2013 Sep; 13 Suppl 2:S317-29.
PMID: 23988451; PMCID: PMC3951475.
Citations:
17 Fields:
Translation:
HumansAnimalsCells
-
Citations:
17 Fields:
Translation:
HumansAnimals
-
DiNardo CD, O'Brien S, Gandhi VV, Ravandi F. Elacytarabine (CP-4055) in the treatment of acute myeloid leukemia. Future Oncol. 2013 Aug; 9(8):1073-82.
PMID: 23902239.
Citations:
4 Fields:
Translation:
Humans
-
Sandoval MR, Balakrishnan K, Luthra R, Keating M, Gandhi V. DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells. Leuk Lymphoma. 2014 Apr; 55(4):876-83.
PMID: 23772636; PMCID: PMC4102412.
Citations:
2 Fields:
Translation:
HumansCells
-
Balakrishnan K, Ravandi F, Bantia S, Franklin A, Gandhi V. Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2013 Aug; 13(4):458-66.
PMID: 23773454; PMCID: PMC4102435.
Citations:
7 Fields:
Translation:
HumansCTClinical Trials
-
Gandhi V, Mehta K, Pathak S, Aggarwal BB. Meeting report: leaders in translational cancer research meet in Udaipur, a historical town of India: an International Symposium onTranslational Cancer Research: Cancer Prevention. Udaipur, Rajasthan, India, december 16-19, 2011. Anticancer Res. 2013 Apr; 33(4):1777-81.
PMID: 23564834.
Citations: Fields:
Translation:
HumansAnimalsCells
-
Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.
PMID: 23091115; PMCID: PMC3567921.
Citations:
463 Fields:
Translation:
HumansAnimalsCells
-
Citations:
24 Fields:
Translation:
HumansAnimalsCells
-
Balakrishnan K, Aggarwal S, Wierda W, Gandhi V. Bax and Bak are required for apogossypolone, a BH3-mimetic, induced apoptosis in chronic lymphocytic leukemia cells. Leuk Lymphoma. 2013 May; 54(5):1097-100.
PMID: 22866921; PMCID: PMC4123740.
Citations:
8 Fields:
Translation:
HumansAnimals
-
McBrayer SK, Yarrington M, Qian J, Feng G, Shanmugam M, Gandhi V, Krett NL, Rosen ST. Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms. PLoS One. 2012; 7(7):e41455.
PMID: 22848499; PMCID: PMC3407247.
Citations:
9 Fields:
Translation:
HumansCells
-
Peng X, Gandhi V. ROS-activated anticancer prodrugs: a new strategy for tumor-specific damage. Ther Deliv. 2012 Jul; 3(7):823-33.
PMID: 22900465; PMCID: PMC3566582.
Citations:
43 Fields:
Translation:
HumansAnimalsCells
-
Gandhi V, Balakrishnan K. CCL2 in chronic lymphocytic leukemia: a macro in microenvironment? Leuk Lymphoma. 2012 Oct; 53(10):1849-50.
PMID: 22563818; PMCID: PMC4123321.
Citations:
2 Fields:
Translation:
Humans
-
Jabbour E, Garcia-Manero G, Cortes J, Ravandi F, Plunkett W, Gandhi V, Faderl S, O'Brien S, Borthakur G, Kadia T, Burger J, Konopleva M, Brandt M, Huang X, Kantarjian H. Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2012 Aug; 12(4):244-51.
PMID: 22534616; PMCID: PMC3859239.
Citations:
9 Fields:
Translation:
HumansCTClinical Trials
-
Pillai RN, Chen LS, Ayres ML, Nowak BJ, Thomas MW, Shpall EJ, Keating MJ, Gandhi V. Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells. Leuk Lymphoma. 2012 Oct; 53(10):2024-32.
PMID: 22448923; PMCID: PMC5648543.
Citations:
1 Fields:
Translation:
HumansCells
-
Balakrishnan K, Gandhi V. Protein kinases: emerging therapeutic targets in chronic lymphocytic leukemia. Expert Opin Investig Drugs. 2012 Apr; 21(4):409-23.
PMID: 22409342; PMCID: PMC4142764.
Citations:
2 Fields:
Translation:
HumansAnimalsCells
-
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012 Feb 02; 119(5):1182-9.
PMID: 22180443; PMCID: PMC4916557.
Citations:
299 Fields:
Translation:
HumansAnimalsCells
-
Tam CS, Gandhi V. Modifying the immune system to treat chronic lymphocytic leukemia. Leuk Lymphoma. 2012 Feb; 53(2):177-8.
PMID: 21895547.
Citations: Fields:
Translation:
Humans
-
Kuang Y, Balakrishnan K, Gandhi V, Peng X. Hydrogen peroxide inducible DNA cross-linking agents: targeted anticancer prodrugs. J Am Chem Soc. 2011 Dec 07; 133(48):19278-81.
PMID: 22035519; PMCID: PMC3265938.
Citations:
56 Fields:
Translation:
HumansCells
-
Cervantes-Gomez F, Nimmanapalli R, Gandhi V. ATP analog enhances the actions of a heat shock protein 90 inhibitor in multiple myeloma cells. J Pharmacol Exp Ther. 2011 Nov; 339(2):545-54.
PMID: 21821695; PMCID: PMC3199983.
Citations:
4 Fields:
Translation:
HumansCells
-
Faderl S, Garcia-Manero G, Jabbour E, Ravandi F, Borthakur G, Estrov Z, Gandhi V, Byrd AL, Kwari M, Cortes J, Kantarjian HM. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer. 2012 Feb 01; 118(3):722-8.
PMID: 21751197; PMCID: PMC4180241.
Citations:
12 Fields:
Translation:
Humans
-
Balakrishnan K, Gandhi V. The micros in harmony: microRNA and microenvironment. Leuk Lymphoma. 2011 Sep; 52(9):1626-9.
PMID: 21740342.
Citations: Fields:
Translation:
HumansCells
-
Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther. 2011 Oct; 339(1):9-23.
PMID: 21712425; PMCID: PMC3186292.
Citations:
28 Fields:
Translation:
HumansCells
-
Chen LS, Redkar S, Taverna P, Cortes JE, Gandhi V. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia. Blood. 2011 Jul 21; 118(3):693-702.
PMID: 21628411; PMCID: PMC3142906.
Citations:
56 Fields:
Translation:
HumansAnimalsCells
-
Lamba JK, Crews KR, Pounds SB, Cao X, Gandhi V, Plunkett W, Razzouk BI, Lamba V, Baker SD, Raimondi SC, Campana D, Pui CH, Downing JR, Rubnitz JE, Ribeiro RC. Identification of predictive markers of cytarabine response in AML by integrative analysis of gene-expression profiles with multiple phenotypes. Pharmacogenomics. 2011 Mar; 12(3):327-39.
PMID: 21449673; PMCID: PMC3139433.
Citations:
14 Fields:
Translation:
Humans
-
Zhang H, Gogada R, Yadav N, Lella RK, Badeaux M, Ayres M, Gandhi V, Tang DG, Chandra D. Defective molecular timer in the absence of nucleotides leads to inefficient caspase activation. PLoS One. 2011 Jan 27; 6(1):e16379.
PMID: 21297999; PMCID: PMC3029307.
Citations:
8 Fields:
Translation:
HumansCells
-
Gandhi V. Yet another nucleoside analog for pancreatic cancer. Gastroenterology. 2011 Feb; 140(2):400-4.
PMID: 21172332.
Citations: Fields:
Translation:
HumansAnimalsCells
-
Gandhi V. Targeting kinases in CML CLL. Blood. 2010 Sep 23; 116(12):1999-2000.
PMID: 20864583.
-
Dennison JB, Shanmugam M, Ayres ML, Qian J, Krett NL, Medeiros LJ, Neelapu SS, Rosen ST, Gandhi V. 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle cell lymphoma. Blood. 2010 Dec 16; 116(25):5622-30.
PMID: 20844237; PMCID: PMC3031409.
Citations:
13 Fields:
Translation:
HumansCells
-
Chen LS, Balakrishnan K, Gandhi V. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol. 2010 Dec 15; 80(12):1936-45.
PMID: 20696142; PMCID: PMC3749885.
Citations:
15 Fields:
Translation:
HumansAnimalsCells
-
Al-Kali A, Gandhi V, Ayoubi M, Keating M, Ravandi F. Forodesine: review of preclinical and clinical data. Future Oncol. 2010 Aug; 6(8):1211-7.
PMID: 20799866.
Citations:
11 Fields:
Translation:
HumansAnimalsCells
-
Chen R, Chubb S, Cheng T, Hawtin RE, Gandhi V, Plunkett W. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 2010 Aug 15; 70(16):6587-97.
PMID: 20663900; PMCID: PMC2929954.
Citations:
16 Fields:
Translation:
HumansCells
-
Gandhi V, Mehta K, Pathak S, Ravindran B, Mishra S, Aggarwal BB. City of temples discusses signaling templates in cancer cells. Third International Symposium on Translational Cancer Research: Cell Signaling & Cancer Therapy. Bhubaneswar, Orissa, India, December 18th through 21st, 2009. Anticancer Res. 2010 Jun; 30(6):2477-80.
PMID: 20651411.
Citations: Fields:
Translation:
HumansAnimalsCells
-
Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, Gandhi V. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood. 2010 Aug 19; 116(7):1083-91.
PMID: 20442367; PMCID: PMC2938131.
Citations:
28 Fields:
Translation:
HumansAnimalsCells
-
Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Gandhi V, Rosenblum MG. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia. 2010 May; 12(5):366-75.
PMID: 20454508; PMCID: PMC2864474.
Citations:
18 Fields:
Translation:
HumansAnimalsCells
-
Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, Tyler BF, Bickel S, Bantia S, Keating MJ, Kantarjian H, Gandhi V, Ravandi F. Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood. 2010 Aug 12; 116(6):886-92.
PMID: 20427701; PMCID: PMC2924226.
Citations:
13 Fields:
Translation:
HumansCellsCTClinical Trials
-
Faderl S, Garcia-Manero G, Estrov Z, Ravandi F, Borthakur G, Cortes JE, O'Brien S, Gandhi V, Plunkett W, Byrd A, Kwari M, Kantarjian HM. Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. J Clin Oncol. 2010 Jun 01; 28(16):2755-60.
PMID: 20421540; PMCID: PMC4872315.
Citations:
19 Fields:
Translation:
HumansCTClinical Trials
-
Dennison JB, Ayres ML, Kaluarachchi K, Plunkett W, Gandhi V. Intracellular succinylation of 8-chloroadenosine and its effect on fumarate levels. J Biol Chem. 2010 Mar 12; 285(11):8022-30.
PMID: 20064937; PMCID: PMC2832953.
Citations:
6 Fields:
Translation:
HumansCells
-
Frey JA, Gandhi V. 8-Amino-adenosine inhibits multiple mechanisms of transcription. Mol Cancer Ther. 2010 Jan; 9(1):236-45.
PMID: 20053765; PMCID: PMC2806509.
Citations:
10 Fields:
Translation:
HumansCells
-
Gandhi V, Burger JA. Bendamustine in B-Cell Malignancies: The New 46-Year-Old Kid on the Block. Clin Cancer Res. 2009 Dec 15; 15(24):7456-7461.
PMID: 19996200; PMCID: PMC2795094.
-
Chen LS, Du-Cuny L, Vethantham V, Hawke DH, Manley JL, Zhang S, Gandhi V. Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analogues. Biochem Pharmacol. 2010 Mar 01; 79(5):669-77.
PMID: 19814999; PMCID: PMC2812641.
Citations:
13 Fields:
Translation:
Animals
-
Burger JA, Gandhi V. The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood. 2009 Sep 17; 114(12):2560-1; author reply 2561-2.
PMID: 19762501; PMCID: PMC4969051.
Citations:
9 Fields:
Translation:
Humans
-
Kurtova AV, Balakrishnan K, Chen R, Ding W, Schnabl S, Quiroga MP, Sivina M, Wierda WG, Estrov Z, Keating MJ, Shehata M, Gandhi V, Kay NE, Plunkett W, Burger JA, J?ger U. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009 Nov 12; 114(20):4441-50.
PMID: 19762485; PMCID: PMC4081374.
Citations:
151 Fields:
Translation:
HumansAnimalsCells
-
Chen LS, Redkar S, Bearss D, Wierda WG, Gandhi V. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2009 Nov 05; 114(19):4150-7.
PMID: 19734450; PMCID: PMC2774551.
Citations:
85 Fields:
Translation:
HumansCells
-
Dennison JB, Balakrishnan K, Gandhi V. Preclinical activity of 8-chloroadenosine with mantle cell lymphoma: roles of energy depletion and inhibition of DNA and RNA synthesis. Br J Haematol. 2009 Nov; 147(3):297-307.
PMID: 19709085; PMCID: PMC2778754.
Citations:
22 Fields:
Translation:
HumansCells
-
Shanmugam M, McBrayer SK, Qian J, Raikoff K, Avram MJ, Singhal S, Gandhi V, Schumacker PT, Krett NL, Rosen ST. Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine. J Biol Chem. 2009 Sep 25; 284(39):26816-30.
PMID: 19648108; PMCID: PMC2785370.
Citations:
25 Fields:
Translation:
HumansCells
-
Stellrecht CM, Ayres M, Arya R, Gandhi V. A unique RNA-directed nucleoside analog is cytotoxic to breast cancer cells and depletes cyclin E levels. Breast Cancer Res Treat. 2010 Jun; 121(2):355-64.
PMID: 19641990; PMCID: PMC5739050.
Citations:
18 Fields:
Translation:
HumansCells
-
Pounds S, Cheng C, Cao X, Crews KR, Plunkett W, Gandhi V, Rubnitz J, Ribeiro RC, Downing JR, Lamba J. PROMISE: a tool to identify genomic features with a specific biologically interesting pattern of associations with multiple endpoint variables. Bioinformatics. 2009 Aug 15; 25(16):2013-9.
PMID: 19528086; PMCID: PMC2723006.
-
Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009 Jul 30; 114(5):1029-37.
PMID: 19491390; PMCID: PMC4916941.
Citations:
103 Fields:
Translation:
HumansAnimalsCells
-
Chen LS, Nowak BJ, Ayres ML, Krett NL, Rosen ST, Zhang S, Gandhi V. Inhibition of ATP synthase by chlorinated adenosine analogue. Biochem Pharmacol. 2009 Sep 15; 78(6):583-91.
PMID: 19477165; PMCID: PMC2763632.
Citations:
17 Fields:
Translation:
Cells
-
Stellrecht CM, Gandhi V. Myeloma antioxidant status: the good, the bad and the reactive. Leuk Lymphoma. 2009 May; 50(5):691-3.
PMID: 19347768.
Citations:
2 Fields:
Translation:
Humans
-
Cervantes-Gomez F, Nimmanapalli R, Gandhi V. Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d. Cancer Res. 2009 May 01; 69(9):3947-54.
PMID: 19383903; PMCID: PMC2778753.
Citations:
6 Fields:
Translation:
HumansCells
-
Rubnitz JE, Crews KR, Pounds S, Yang S, Campana D, Gandhi VV, Raimondi SC, Downing JR, Razzouk BI, Pui CH, Ribeiro RC. Combination of cladribine and cytarabine is effective for childhood acute myeloid leukemia: results of the St Jude AML97 trial. Leukemia. 2009 Aug; 23(8):1410-6.
PMID: 19242495; PMCID: PMC2726271.
Citations:
27 Fields:
Translation:
Humans
-
Guo Y, Ritter CA, Chen ZS, Grube M, Jedlitschky G, Illmer T, Ayres M, Beck JF, Siegmund W, Ehninger G, Gandhi V, Kroemer HK, Kruh GD, Schaich M, K?ck K. Expression of ABCC-type nucleotide exporters in blasts of adult acute myeloid leukemia: relation to long-term survival. Clin Cancer Res. 2009 Mar 01; 15(5):1762-9.
PMID: 19240178; PMCID: PMC5744661.
Citations:
32 Fields:
Translation:
HumansCells
-
Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, Gandhi V, Plunkett W. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 07; 113(19):4637-45.
PMID: 19234140; PMCID: PMC2680368.
Citations:
79 Fields:
Translation:
HumansCells
-
Sampath D, Gandhi V. Dialing resistance up a Notch. Leuk Lymphoma. 2009 Feb; 50(2):158-9.
PMID: 19235014.
Citations: Fields:
Translation:
HumansCells
-
Gandhi V, S?nchez-Vega B. Glucocorticoid resistance in a multiple myeloma cell line is regulated by a transcription elongation block in the glucocorticoid receptor gene (NR3C1). Br J Haematol. 2009 Mar; 144(6):856-64.
PMID: 19133980; PMCID: PMC4303606.
Citations:
10 Fields:
Translation:
HumansCells
-
Stellrecht CM, Gandhi V. MET receptor tyrosine kinase as a therapeutic anticancer target. Cancer Lett. 2009 Jul 18; 280(1):1-14.
PMID: 19100682.
Citations:
18 Fields:
Translation:
HumansCells
-
Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH. Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival. Cancer. 2008 Dec 01; 113(11):3181-5.
PMID: 18932257; PMCID: PMC4126078.
Citations:
27 Fields:
Translation:
HumansCTClinical Trials
-
-
Citations:
68 Fields:
Translation:
HumansCells
-
Citations:
38 Fields:
Translation:
HumansCells
-
Phillip CJ, Stellrecht CM, Nimmanapalli R, Gandhi V. Targeting MET transcription as a therapeutic strategy in multiple myeloma. Cancer Chemother Pharmacol. 2009 Mar; 63(4):587-97.
PMID: 18509644; PMCID: PMC2892885.
Citations:
11 Fields:
Translation:
HumansCells
-
Nimmanapalli R, Gerbino E, Dalton WS, Gandhi V, Alsina M. HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma. Br J Haematol. 2008 Aug; 142(4):551-61.
PMID: 18503584; PMCID: PMC4503206.
Citations:
21 Fields:
Translation:
HumansCells
-
Chen LS, Plunkett W, Gandhi V. Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues. Leuk Res. 2008 Oct; 32(10):1573-81.
PMID: 18433867; PMCID: PMC4048126.
Citations:
4 Fields:
Translation:
Cells
-
Faderl S, Gandhi V, Kantarjian HM. Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia. Curr Opin Hematol. 2008 Mar; 15(2):101-7.
PMID: 18300755.
Citations:
4 Fields:
Translation:
Humans
-
Gandhi V, Tam C, O'Brien S, Jewell RC, Rodriguez CO, Lerner S, Plunkett W, Keating MJ. Phase I trial of nelarabine in indolent leukemias. J Clin Oncol. 2008 Mar 01; 26(7):1098-105.
PMID: 18309944.
Citations:
12 Fields:
Translation:
HumansCellsCTClinical Trials
-
Chen LS, Stellrecht CM, Gandhi V. RNA-directed agent, cordycepin, induces cell death in multiple myeloma cells. Br J Haematol. 2008 Mar; 140(6):682-391.
PMID: 18205859.
Citations:
25 Fields:
Translation:
HumansCells
-
Gandhi V. Questions about gemcitabine dose rate: answered or unanswered? J Clin Oncol. 2007 Dec 20; 25(36):5691-4.
PMID: 18089862.
Citations:
5 Fields:
Translation:
Humans
-
Gandhi V, Balakrishnan K. Pharmacology and mechanism of action of forodesine, a T-cell targeted agent. Semin Oncol. 2007 Dec; 34(6 Suppl 5):S8-12.
PMID: 18086347.
Citations:
11 Fields:
Translation:
HumansCells
-
Stellrecht CM, Phillip CJ, Cervantes-Gomez F, Gandhi V. Multiple myeloma cell killing by depletion of the MET receptor tyrosine kinase. Cancer Res. 2007 Oct 15; 67(20):9913-20.
PMID: 17942923.
Citations:
21 Fields:
Translation:
Humans
-
Tili E, Michaille JJ, Gandhi V, Plunkett W, Sampath D, Calin GA. miRNAs and their potential for use against cancer and other diseases. Future Oncol. 2007 Oct; 3(5):521-37.
PMID: 17927518.
Citations:
47 Fields:
Translation:
HumansAnimals
-
Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S. Clofarabine: past, present, and future. Leuk Lymphoma. 2007 Oct; 48(10):1922-30.
PMID: 17852710.
Citations:
25 Fields:
Translation:
HumansAnimals
-
Lamba JK, Crews K, Pounds S, Schuetz EG, Gresham J, Gandhi V, Plunkett W, Rubnitz J, Ribeiro R. Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants. J Pharmacol Exp Ther. 2007 Dec; 323(3):935-45.
PMID: 17855478.
Citations:
42 Fields:
Translation:
HumansCells
-
Flanagan SA, Gandhi V, Meckling KA. Guanosine acts intracellularly to initiate apoptosis in NB4 cells: A role for nucleoside transport. Leuk Lymphoma. 2007 Sep; 48(9):1816-27.
PMID: 17786719.
Citations:
3 Fields:
Translation:
HumansCells
-
Karp JE, Ricklis RM, Balakrishnan K, Briel J, Greer J, Gore SD, Smith BD, McDevitt MA, Carraway H, Levis MJ, Gandhi V. A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias. Blood. 2007 Sep 15; 110(6):1762-9.
PMID: 17562873; PMCID: PMC1976362.
Citations:
31 Fields:
Translation:
HumansCellsCTClinical Trials
-
Gandhi V. p53 as a predictor for chemotherapy response in CLL cells. Leuk Lymphoma. 2007 Feb; 48(2):219-20.
PMID: 17325877.
Citations:
1 Fields:
Translation:
Humans
-
Ravandi F, Gandhi V. Novel purine nucleoside analogues for T-cell-lineage acute lymphoblastic leukaemia and lymphoma. Expert Opin Investig Drugs. 2006 Dec; 15(12):1601-13.
PMID: 17107284.
Citations:
18 Fields:
Translation:
HumansAnimalsCells
-
Krett N, Rosen ST, Gandhi V, S?nchez-Vega B. Glucocorticoid receptor transcriptional isoforms and resistance in multiple myeloma cells. Mol Cancer Ther. 2006 Dec; 5(12):3062-70.
PMID: 17172408.
Citations:
16 Fields:
Translation:
HumansCells
-
Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG, Gandhi V. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood. 2007 Mar 15; 109(6):2557-64.
PMID: 17119117.
Citations:
14 Fields:
Translation:
HumansCells
-
Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res. 2006 Nov 15; 66(22):10959-66.
PMID: 17108134.
Citations:
30 Fields:
Translation:
HumansCells
-
Gandhi V, Plunkett W. Clofarabine and nelarabine: two new purine nucleoside analogs. Curr Opin Oncol. 2006 Nov; 18(6):584-90.
PMID: 16988579.
Citations:
13 Fields:
Translation:
Humans
-
Gandhi V, Plunkett W, Bonate PL, Du M, Nowak B, Lerner S, Keating MJ. Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment. Clin Cancer Res. 2006 Jul 01; 12(13):4011-7.
PMID: 16818700.
Citations:
4 Fields:
Translation:
HumansCellsCTClinical Trials
-
Chandra D, Bratton SB, Person MD, Tian Y, Martin AG, Ayres M, Fearnhead HO, Gandhi V, Tang DG. Intracellular nucleotides act as critical prosurvival factors by binding to cytochrome C and inhibiting apoptosome. Cell. 2006 Jun 30; 125(7):1333-46.
PMID: 16814719.
Citations:
55 Fields:
Translation:
HumansCells
-
Balakrishnan K, Nimmanapalli R, Ravandi F, Keating MJ, Gandhi V. Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood. 2006 Oct 01; 108(7):2392-8.
PMID: 16778146; PMCID: PMC1895565.
Citations:
27 Fields:
Translation:
HumansCells
-
Mehta K, Gandhi V, Aggarwal BB. All pathways to cancer apoptosis meeting in Thiruvananthapuram (India). Cell Death Differ. 2006 Dec; 13(12):2163-4.
PMID: 16741526.
Citations: Fields:
Translation:
HumansAnimalsCells
-
Gandhi V, Keating MJ, Bate G, Kirkpatrick P. Nelarabine. Nat Rev Drug Discov. 2006 Jan; 5(1):17-8.
PMID: 16485343.
Citations:
9 Fields:
Translation:
HumansCells
-
Sampath D, Cortes J, Estrov Z, Du M, Shi Z, Andreeff M, Gandhi V, Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006 Mar 15; 107(6):2517-24.
PMID: 16293603; PMCID: PMC1895741.
Citations:
54 Fields:
Translation:
HumansCellsCTClinical Trials
-
Balakrishnan K, Wierda WG, Keating MJ, Gandhi V. Mechanisms of cell death of chronic lymphocytic leukemia lymphocytes by RNA-directed agent, 8-NH2-adenosine. Clin Cancer Res. 2005 Sep 15; 11(18):6745-52.
PMID: 16166456.
Citations:
9 Fields:
Translation:
HumansCells
-
Gandhi V, Kilpatrick JM, Plunkett W, Ayres M, Harman L, Du M, Bantia S, Davisson J, Wierda WG, Faderl S, Kantarjian H, Thomas D. A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine). Blood. 2005 Dec 15; 106(13):4253-60.
PMID: 16131572; PMCID: PMC1895256.
Citations:
28 Fields:
Translation:
HumansCellsCTClinical Trials
-
Jabbour E, Verstovsek S, Giles F, Gandhi V, Cortes J, O'Brien S, Plunkett W, Garcia-Manero G, Jackson CE, Kantarjian H, Andreeff M. 2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome. Cancer. 2005 Aug 01; 104(3):541-6.
PMID: 15977212.
Citations:
4 Fields:
Translation:
Humans
-
Chen R, Keating MJ, Gandhi V, Plunkett W. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005 Oct 01; 106(7):2513-9.
PMID: 15972445; PMCID: PMC1895272.
Citations:
116 Fields:
Translation:
HumansCells
-
Kurtzberg J, Ernst TJ, Keating MJ, Gandhi V, Hodge JP, Kisor DF, Lager JJ, Stephens C, Levin J, Krenitsky T, Elion G, Mitchell BS. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol. 2005 May 20; 23(15):3396-403.
PMID: 15908652.
Citations:
38 Fields:
Translation:
HumansCTClinical Trials
-
Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM. The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog. Cancer. 2005 May 15; 103(10):1985-95.
PMID: 15803490.
Citations:
22 Fields:
Translation:
Humans
-
Ghias K, Ma C, Gandhi V, Platanias LC, Krett NL, Rosen ST. 8-Amino-adenosine induces loss of phosphorylation of p38 mitogen-activated protein kinase, extracellular signal-regulated kinase 1/2, and Akt kinase: role in induction of apoptosis in multiple myeloma. Mol Cancer Ther. 2005 Apr; 4(4):569-77.
PMID: 15827330.
Citations:
15 Fields:
Translation:
HumansCells
-
Balakrishnan K, Stellrecht CM, Genini D, Ayres M, Wierda WG, Keating MJ, Leoni LM, Gandhi V. Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood. 2005 Jun 01; 105(11):4455-62.
PMID: 15718423; PMCID: PMC1895042.
Citations:
26 Fields:
Translation:
HumansCells
-
Bonate PL, Craig A, Gaynon P, Gandhi V, Jeha S, Kadota R, Lam GN, Plunkett W, Razzouk B, Rytting M, Steinherz P, Weitman S. Population pharmacokinetics of clofarabine, a second-generation nucleoside analog, in pediatric patients with acute leukemia. J Clin Pharmacol. 2004 Nov; 44(11):1309-22.
PMID: 15496649.
Citations:
12 Fields:
Translation:
Humans
-
Krett NL, Davies KM, Ayres M, Ma C, Nabhan C, Gandhi V, Rosen ST. 8-amino-adenosine is a potential therapeutic agent for multiple myeloma. Mol Cancer Ther. 2004 Nov; 3(11):1411-20.
PMID: 15542780.
Citations:
15 Fields:
Translation:
HumansCells
-
Cooper T, Ayres M, Nowak B, Gandhi V. Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol. 2005 Apr; 55(4):361-368.
PMID: 15723262.
Citations:
27 Fields:
Translation:
HumansCells
-
Faderl S, Gandhi V, O'Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H. Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood. 2005 Feb 01; 105(3):940-7.
PMID: 15486072.
Citations:
57 Fields:
Translation:
HumansCTClinical Trials
-
Cooper T, Kantarjian H, Plunkett W, Gandhi V. Clofarabine in adult acute leukemias: clinical success and pharmacokinetics. Nucleosides Nucleotides Nucleic Acids. 2004 Oct; 23(8-9):1417-23.
PMID: 15571270.
Citations:
1 Fields:
Translation:
HumansCTClinical Trials
-
Krett NL, Ayres M, Nabhan C, Ma C, Nowak B, Nawrocki S, Rosen ST, Gandhi V. In vitro assessment of nucleoside analogs in multiple myeloma. Cancer Chemother Pharmacol. 2004 Aug; 54(2):113-21.
PMID: 15133625.
Citations:
4 Fields:
Translation:
HumansCells
-
Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W. Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res. 2003 Dec 15; 9(17):6335-42.
PMID: 14695132.
Citations:
16 Fields:
Translation:
HumansCellsCTClinical Trials
-
Giles FJ, Fracasso PM, Kantarjian HM, Cortes JE, Brown RA, Verstovsek S, Alvarado Y, Thomas DA, Faderl S, Garcia-Manero G, Wright LP, Samson T, Cahill A, Lambert P, Plunkett W, Sznol M, DiPersio JF, Gandhi V. Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia. Leuk Res. 2003 Dec; 27(12):1077-83.
PMID: 12921943.
Citations:
32 Fields:
Translation:
HumansCTClinical Trials
-
Stellrecht CM, Rodriguez CO, Ayres M, Gandhi V. RNA-directed actions of 8-chloro-adenosine in multiple myeloma cells. Cancer Res. 2003 Nov 15; 63(22):7968-74.
PMID: 14633728.
Citations:
28 Fields:
Translation:
HumansCells
-
Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Brandt M, Keating M, Plunkett W, Kantarjian H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood. 2004 Feb 01; 103(3):784-9.
PMID: 14551141.
Citations:
73 Fields:
Translation:
HumansCTClinical Trials
-
Flanagan SA, Gandhi V, Secrist JA, Meckling KA. The novel nucleoside transport system exhibited by NB4 cells, csg, transports deoxyguanosine analogues, including ara-G. Biochem Pharmacol. 2003 Sep 01; 66(5):733-7.
PMID: 12948853.
Citations:
1 Fields:
Translation:
HumansCells
-
Kantarjian H, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O'Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood. 2003 Oct 01; 102(7):2379-86.
PMID: 12791647.
Citations:
80 Fields:
Translation:
HumansCTClinical Trials
-
Rodriguez CO, Stellrecht CM, Gandhi V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood. 2003 Sep 01; 102(5):1842-8.
PMID: 12750168.
Citations:
31 Fields:
Translation:
HumansCells
-
Wright K, Popli S, Gandhi VC, Lentino JR, Reyes CV, Leehey DJ. Paecilomyces peritonitis: case report and review of the literature. Clin Nephrol. 2003 Apr; 59(4):305-10.
PMID: 12708573.
Citations:
5 Fields:
Translation:
HumansAnimals
-
Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol. 2003 Mar 15; 21(6):1167-73.
PMID: 12637486.
Citations:
49 Fields:
Translation:
HumansCTClinical Trials
-
Sharma GG, Gupta A, Wang H, Scherthan H, Dhar S, Gandhi V, Iliakis G, Shay JW, Young CS, Pandita TK. hTERT associates with human telomeres and enhances genomic stability and DNA repair. Oncogene. 2003 Jan 09; 22(1):131-46.
PMID: 12527915.
Citations:
85 Fields:
Translation:
HumansCells
-
Stellrecht CM, Gandhi V. Concurrent isolation of ribosomal, messenger, and low molecular weight RNA. Biotechniques. 2002 Nov; 33(5):1122-4.
PMID: 12449393.
Citations: Fields:
Translation:
HumansCells
-
Nabhan C, Gajria D, Krett NL, Gandhi V, Ghias K, Rosen ST. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines. Mol Cancer Ther. 2002 Nov; 1(13):1221-7.
PMID: 12479703.
Citations:
11 Fields:
Translation:
HumansCells
-
Crews KR, Gandhi V, Srivastava DK, Razzouk BI, Tong X, Behm FG, Plunkett W, Raimondi SC, Pui CH, Rubnitz JE, Stewart CF, Ribeiro RC. Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol. 2002 Oct 15; 20(20):4217-24.
PMID: 12377965.
Citations:
12 Fields:
Translation:
HumansCTClinical Trials
-
Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol. 2002 Aug; 29(4 Suppl 13):4-11.
PMID: 12170425.
Citations:
32 Fields:
Translation:
HumansCells
-
Gandhi V, Chen W, Ayres M, Rhie JK, Madden TL, Newman RA. Plasma and cellular pharmacology of 8-chloro-adenosine in mice and rats. Cancer Chemother Pharmacol. 2002 Aug; 50(2):85-94.
PMID: 12172971.
Citations:
10 Fields:
Translation:
AnimalsCells
-
Rodriguez CO, Mitchell BS, Ayres M, Eriksson S, Gandhi V. Arabinosylguanine is phosphorylated by both cytoplasmic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. Cancer Res. 2002 Jun 01; 62(11):3100-5.
PMID: 12036920.
Citations:
25 Fields:
Translation:
HumansCells
-
Lin-Lee YC, Nakamura S, Gandhi V, Curley SA, Burkot TR, Kuo MT, St?ber D. Prolonged stability and sustained prodrug cell killing activity using receptor-mediated delivery of malarial circumsporozoite-cytosine deaminase fusion protein into liver cancer cells. Mol Cancer Ther. 2002 May; 1(7):461-7.
PMID: 12479264.
Citations:
1 Fields:
Translation:
HumansCells
-
Gandhi V, Plunkett W, Du M, Ayres M, Estey EH. Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002 Feb 01; 20(3):665-73.
PMID: 11821446.
Citations:
18 Fields:
Translation:
HumansCTClinical Trials
-
Faderl S, Gandhi V, Kantarjian H, Plunkett W. New nucleoside analogues in clinical development. Cancer Chemother Biol Response Modif. 2002; 20:37-58.
PMID: 12703199.
Citations:
1 Fields:
Translation:
HumansAnimals
-
Gandhi V, Plunkett W. Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet. 2002; 41(2):93-103.
PMID: 11888330.
Citations:
87 Fields:
Translation:
HumansCells
-
Zhou Y, Achanta G, Pelicano H, Gandhi V, Plunkett W, Huang P. Action of (E)-2'-deoxy-2'-(fluoromethylene)cytidine on DNA metabolism: incorporation, excision, and cellular response. Mol Pharmacol. 2002 Jan; 61(1):222-9.
PMID: 11752224.
Citations:
7 Fields:
Translation:
HumansCells
-
Nabhan C, Krett N, Gandhi V, Rosen S. Gemcitabine in hematologic malignancies. Curr Opin Oncol. 2001 Nov; 13(6):514-21.
PMID: 11673693.
Citations:
9 Fields:
Translation:
HumansCells
-
Patel SR, Gandhi V, Jenkins J, Papadopolous N, Burgess MA, Plager C, Plunkett W, Benjamin RS. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001 Aug 01; 19(15):3483-9.
PMID: 11481354.
Citations:
65 Fields:
Translation:
HumansCellsCTClinical Trials
-
Gandhi V, Ayres M, Halgren RG, Krett NL, Newman RA, Rosen ST. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells. Cancer Res. 2001 Jul 15; 61(14):5474-9.
PMID: 11454694.
Citations:
42 Fields:
Translation:
HumansCells
-
Gandhi V, Plunkett W, Weller S, Du M, Ayres M, Rodriguez CO, Ramakrishna P, Rosner GL, Hodge JP, O'Brien S, Keating MJ. Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells. J Clin Oncol. 2001 Apr 15; 19(8):2142-52.
PMID: 11304766.
Citations:
8 Fields:
Translation:
HumansCTClinical Trials
-
Plunkett W, Gandhi V. Purine and pyrimidine nucleoside analogs. Cancer Chemother Biol Response Modif. 2001; 19:21-45.
PMID: 11686015.
Citations:
17 Fields:
Translation:
HumansAnimals
-
Rodriguez CO, Plunkett W, Paff MT, Du M, Nowak B, Ramakrishna P, Keating MJ, Gandhi V. High-performance liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B Biomed Sci Appl. 2000 Aug 18; 745(2):421-30.
PMID: 11043760.
Citations:
10 Fields:
Translation:
HumansCells
-
Kisor DF, Plunkett W, Kurtzberg J, Mitchell B, Hodge JP, Ernst T, Keating MJ, Gandhi V. Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol. 2000 Mar; 18(5):995-1003.
PMID: 10694549.
Citations:
15 Fields:
Translation:
HumansCTClinical Trials
-
Giles FJ, O'Brien SM, Santini V, Gandhi V, Plunkett W, Seymour JF, Robertson LE, Kantarjian HM, Keating MJ. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study. Leuk Lymphoma. 1999 Dec; 36(1-2):57-65.
PMID: 10613450.
Citations:
6 Fields:
Translation:
HumansCTClinical Trials
-
Rodriguez CO, Gandhi V. Arabinosylguanine-induced apoptosis of T-lymphoblastic cells: incorporation into DNA is a necessary step. Cancer Res. 1999 Oct 01; 59(19):4937-43.
PMID: 10519407.
Citations:
15 Fields:
Translation:
HumansCells
-
Fabianowska-Majewska K, Mantincic D, Callet Bauchu E, Tigaud I, Gandhi V, Lepoivre M, Peters GJ, Rolland MO, Wyczechowska D, Fang X, Gazzo S, Voorn DA, Vanier-Viornery A, MacKey J, Dumontet C. Common resistance mechanisms to deoxynucleoside analogues in variants of the human erythroleukaemic line K562. Br J Haematol. 1999 Jul; 106(1):78-85.
PMID: 10444166.
Citations:
31 Fields:
Translation:
HumansCells
-
Aguayo A, Cortes JE, Kantarjian HM, Beran M, Gandhi V, Plunkett W, Kurtzberg J, Keating MJ. Complete hematologic and cytogenetic response to 2-amino-9-beta-D-arabinosyl-6-methoxy-9H-guanine in a patient with chronic myelogenous leukemia in T-cell blastic phase: a case report and review of the literature. Cancer. 1999 Jan 01; 85(1):58-64.
PMID: 9921974.
Citations:
5 Fields:
Translation:
HumansCells
-
Gandhi V, Plunkett W, Rodriguez CO, Nowak BJ, Du M, Ayres M, Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol. 1998 Nov; 16(11):3607-15.
PMID: 9817282.
Citations:
20 Fields:
Translation:
HumansCTClinical Trials
-
Gandhi V, Plunkett W, Kantarjian H, Talpaz M, Robertson LE, O'Brien S. Cellular pharmacodynamics and plasma pharmacokinetics of parenterally infused hydroxyurea during a phase I clinical trial in chronic myelogenous leukemia. J Clin Oncol. 1998 Jul; 16(7):2321-31.
PMID: 9667246.
-
Gandhi V, Xu YZ, Estey E. Accumulation of arabinosyluracil 5'-triphosphate during arabinosylcytosine therapy in circulating blasts of patients with acute myelogenous leukemia. Clin Cancer Res. 1998 Jul; 4(7):1719-26.
PMID: 9676847.
Citations:
5 Fields:
Translation:
Humans
-
Rodriguez CO, Legha JK, Estey E, Keating MJ, Gandhi V. Pharmacological and biochemical strategies to increase the accumulation of arabinofuranosylguanine triphosphatein primary human leukemia cells. Clin Cancer Res. 1997 Nov; 3(11):2107-13.
PMID: 9815603.
Citations:
4 Fields:
Translation:
Humans
-
Gandhi V, Estey E, Du M, Keating MJ, Plunkett W. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997 Sep; 3(9):1539-45.
PMID: 9815841.
Citations:
14 Fields:
Translation:
HumansCells
-
Gandhi V, Huang P, Chapman AJ, Chen F, Plunkett W. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin Cancer Res. 1997 Aug; 3(8):1347-55.
PMID: 9815818.
Citations:
9 Fields:
Translation:
HumansCells
-
Plunkett W, Gandhi V. Pharmacology of purine nucleoside analogues. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S67-74.
PMID: 9137959.
Citations:
2 Fields:
Translation:
HumansAnimals
-
Keating MJ, O'Brien S, McLaughlin P, Dimopoulos M, Gandhi V, Plunkett W, Lerner S, Kantarjian H, Estey E. Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996 Dec; 38 Suppl 2:S83-91.
PMID: 9137961.
Citations:
3 Fields:
Translation:
Humans
-
Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res. 1996 Oct 01; 56(19):4453-9.
PMID: 8813140.
-
Kornblau SM, Gandhi V, Andreeff HM, Beran M, Kantarjian HM, Koller CA, O'Brien S, Plunkett W, Estey E. Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults. Leukemia. 1996 Oct; 10(10):1563-9.
PMID: 8847890.
Citations:
13 Fields:
Translation:
HumansCTClinical Trials
-
Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996 Oct; 23(5 Suppl 10):3-15.
PMID: 8893876.
Citations:
95 Fields:
Translation:
HumansAnimals
-
Gandhi V, Estey EH, Keating MJ, Plunkett W. Intracellular pharmacodynamics in leukemia therapy. Rinsho Ketsueki. 1996 May; 37(5):369-79.
PMID: 8691580.
Citations: Fields:
Translation:
Humans
-
Seymour JF, Huang P, Plunkett W, Gandhi V. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996 Apr; 2(4):653-8.
PMID: 9816215.
Citations:
12 Fields:
Translation:
HumansCells
-
Gandhi V, Estey E, Keating MJ, Chucrallah A, Plunkett W. Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions. Blood. 1996 Jan 01; 87(1):256-64.
PMID: 8547650.
Citations:
30 Fields:
Translation:
HumansCellsCTClinical Trials
-
Loughlin S, Gandhi V, Plunkett W, Zwelling LA. The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells. Cancer Chemother Pharmacol. 1996; 38(3):261-8.
PMID: 8646801.
Citations: Fields:
Translation:
HumansCells
-
Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995 Dec; 6 Suppl 6:7-13.
PMID: 8718419.
Citations:
56 Fields:
Translation:
HumansAnimalsCells
-
Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug; 22(4 Suppl 11):3-10.
PMID: 7481842.
Citations:
223 Fields:
Translation:
HumansAnimalsCells
-
Gandhi V, Mineishi S, Huang P, Yang Y, Chubb S, Chapman AJ, Nowak BJ, Hertel LW, Plunkett W. Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 1995 Aug; 22(4 Suppl 11):61-7.
PMID: 7481847.
Citations:
5 Fields:
Translation:
HumansAnimalsCells
-
Gandhi V, Mineishi S, Huang P, Chapman AJ, Yang Y, Chen F, Nowak B, Chubb S, Hertel LW, Plunkett W. Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res. 1995 Apr 01; 55(7):1517-24.
PMID: 7533664.
Citations:
10 Fields:
Translation:
AnimalsCells
-
Gandhi V, Estey E, Du M, Nowak B, Keating MJ, Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995 Feb; 1(2):169-78.
PMID: 9815970.
Citations:
21 Fields:
Translation:
HumansCTClinical Trials
-
Gandhi V, Du M, Kantarjian HM, Plunkett W. Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia. 1994 Sep; 8(9):1463-8.
PMID: 8090026.
Citations: Fields:
Translation:
HumansCells
-
Plunkett W, Gandhi V. Evolution of the arabinosides and the pharmacology of fludarabine. Drugs. 1994; 47 Suppl 6:30-8.
PMID: 7525187.
Citations:
2 Fields:
Translation:
HumansAnimals
-
Gandhi V, Estey E, Plunkett W. Modulation of arabinosylcytosine metabolism during leukemia therapy. Adv Exp Med Biol. 1994; 370:119-24.
PMID: 7544948.
Citations:
2 Fields:
Translation:
Humans
-
Gandhi V, Huang P, Plunkett W. Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma. 1994; 14 Suppl 2:3-9.
PMID: 7881348.
Citations:
4 Fields:
Translation:
HumansAnimalsCells
-
Keating MJ, O'Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol. 1994 Jan; 31(1):28-39.
PMID: 7510070.
Citations:
5 Fields:
Translation:
HumansAnimals
-
Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol. 1994; 34(1):30-6.
PMID: 8174200.
Citations:
4 Fields:
Translation:
Humans
-
Keating MJ, McLaughlin P, Plunkett W, Robertson LE, O'Brien S, Gandhi V, Gregoire V, Yang L, Cabanillas F. Fludarabine--present status and future developments in chronic lymphocytic leukemia and lymphoma. Ann Oncol. 1994; 5 Suppl 2:79-83.
PMID: 8204523.
Citations:
2 Fields:
Translation:
HumansCells
-
Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Li YY, Gandhi V, et al. The expanding role of fludarabine in hematologic malignancies. Leuk Lymphoma. 1994; 14 Suppl 2:11-6.
PMID: 7533576.
Citations:
2 Fields:
Translation:
Humans
-
Keating MJ, O'Brien S, Robertson LE, Kantarjian H, Dimopoulos M, McLaughlin P, Cabanillas F, Gregoire V, Yang LY, Gandhi V, et al. New initiatives with fludarabine monophosphate in hematologic malignancies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):13-20.
PMID: 7694371.
Citations:
1 Fields:
Translation:
Humans
-
Plunkett W, Gandhi V, Huang P, Robertson LE, Yang LY, Gregoire V, Estey E, Keating MJ. Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):2-12.
PMID: 8235690.
Citations:
30 Fields:
Translation:
Humans
-
Suki S, Kantarjian H, Gandhi V, Estey E, O'Brien S, Beran M, Rios MB, Plunkett W, Keating M. Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer. 1993 Oct 01; 72(7):2155-60.
PMID: 8374873.
Citations:
7 Fields:
Translation:
HumansCTClinical Trials
-
Gandhi V, Kemena A, Keating MJ, Plunkett W. Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma. 1993 May; 10(1-2):49-56.
PMID: 8374523.
Citations:
12 Fields:
Translation:
HumansCellsCTClinical Trials
-
Estey E, Plunkett W, Gandhi V, Rios MB, Kantarjian H, Keating MJ. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993 Mar; 9(4-5):343-50.
PMID: 8394169.
Citations:
20 Fields:
Translation:
HumansCTClinical Trials
-
Plunkett W, Gandhi V. Cellular pharmacodynamics of anticancer drugs. Semin Oncol. 1993 Feb; 20(1):50-63.
PMID: 8475410.
Citations:
10 Fields:
Translation:
Humans
-
Gandhi V. Fludarabine for treatment of adult acute myelogenous leukemia. Leuk Lymphoma. 1993; 11 Suppl 2:7-13.
PMID: 8124234.
Citations: Fields:
Translation:
Humans
-
Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993 Jan; 11(1):116-24.
PMID: 8418222.
Citations:
64 Fields:
Translation:
Humans
-
Gandhi V, Estey E, Keating MJ, Plunkett W. Biochemical modulation of arabinosylcytosine for therapy of leukemias. Leuk Lymphoma. 1993; 10 Suppl:109-14.
PMID: 8481660.
Citations:
13 Fields:
Translation:
Humans
-
Yu AW, Soundararajan R, Nawab ZM, Gandhi VC, Rahman MA, Popli S, Ing TS. Raising plasma phosphorus levels by phosphorus-enriched, bicarbonate-containing dialysate in hemodialysis patients. Artif Organs. 1992 Aug; 16(4):414-6.
PMID: 10078284.
Citations: Fields:
Translation:
Humans
-
Gandhi V, Kemena A, Keating MJ, Plunkett W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992 Feb 15; 52(4):897-903.
PMID: 1737352.
Citations:
18 Fields:
Translation:
HumansCells
-
Gandhi V, Plunkett W. Cell cycle-specific metabolism of arabinosyl nucleosides in K562 human leukemia cells. Cancer Chemother Pharmacol. 1992; 31(1):11-7.
PMID: 1458554.
Citations:
4 Fields:
Translation:
HumansCells
-
Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W. Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol. 1992; 31(3):193-9.
PMID: 1464155.
Citations:
5 Fields:
Translation:
HumansCells
-
Yu AW, Manahan FJ, Filkins JP, Mohammed MS, Soundararajan R, McShane AP, Gandhi VC, Ing TS. Peritoneal dialysis using bicarbonate-containing solution sterilized by ultrafiltration. Int J Artif Organs. 1991 Aug; 14(8):463-5.
PMID: 1937936.
Citations: Fields:
Translation:
HumansCellsPHPublic Health
-
Gandhi V, Huang P, Xu YZ, Heinemann V, Plunkett W. Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol. 1991; 309A:125-30.
PMID: 1789190.
Citations:
6 Fields:
Translation:
HumansCells
-
Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol. 1990 Oct; 17(5 Suppl 8):3-17.
PMID: 1699280.
Citations:
26 Fields:
Translation:
HumansAnimalsCells
-
Gandhi V, Plunkett W. Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res. 1990 Jun 15; 50(12):3675-80.
PMID: 2340517.
Citations:
37 Fields:
Translation:
HumansCells
-
Gandhi V, Nowak B, Keating MJ, Plunkett W. Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood. 1989 Nov 01; 74(6):2070-5.
PMID: 2478221.
Citations:
11 Fields:
Translation:
HumansCells
-
Gandhi V, Plunkett W. Interaction of arabinosyl nucleotides in K562 human leukemia cells. Biochem Pharmacol. 1989 Oct 15; 38(20):3551-8.
PMID: 2479383.
Citations:
3 Fields:
Translation:
HumansCells
-
Gandhi VC, Jones DJ. Identification and characterization of [3H]nitrendipine binding sites in rat spinal cord. J Pharmacol Exp Ther. 1988 Nov; 247(2):473-80.
PMID: 2460614.
Citations:
1 Fields:
Translation:
Animals
-
Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988 Jan 15; 48(2):329-34.
PMID: 3335008.
Citations:
29 Fields:
Translation:
HumansCells
-
Gandhi VC, Ross DH. A novel kappa agonist inhibits [3H]nimodipine binding to a Ca++ channel receptor protein in rat brain. Biochem Biophys Res Commun. 1987 Dec 31; 149(3):1042-8.
PMID: 2447885.
Citations: Fields:
Translation:
AnimalsCells
-
Danhauser L, Plunkett W, Liliemark J, Gandhi V, Iacoboni S, Keating M. Comparison between the plasma and intracellular pharmacology of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate in patients with relapsed leukemia. Leukemia. 1987 Sep; 1(9):638-43.
PMID: 3478543.
Citations:
14 Fields:
Translation:
HumansCells
-
Gandhi V, Danhauser L, Plunkett W. Separation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate and 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-triphosphate in human leukemia cells by high-performance liquid chromatography. J Chromatogr. 1987 Jan 23; 413:293-9.
PMID: 3558682.
Citations:
5 Fields:
Translation:
HumansCells
-
Sharp ZD, Gandhi VV, Procunier JD. X chromosome nucleolus organizer mutants which alter major type I repeat multiplicity in Drosophila melanogaster. Mol Gen Genet. 1983; 190(3):438-43.
PMID: 6308398.
Citations:
6 Fields:
Translation:
AnimalsCells
-
Gandhi VV, Sharp ZD, Procunier JD. Analysis of Y chromosome nucleolar organizer mutants in Drosophila melanogaster. Biochem Biophys Res Commun. 1982 Jan 29; 104(2):778-84.
PMID: 6803790.
Citations:
4 Fields:
Translation:
AnimalsCells
-
Bendamustine in B-cell malignancies. Clinical Cancer Research. 15:7456-7461.
-
Clofarabine in paediatric patients with acute lymphoblastic leukaemia. Drugs and Therapy Perspectives. 22:3-5.
-
2',2'-difluorodeoxycytidine metabolism and mechanism of action in human leukemia cells. Nucleosides and Nucleotides. 8:775-785.
-
Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clinical Cancer Research. 21:3705-3715.
-
Gemcitabine. Nucleosides and Nucleotides. 16:1261-1270.
-
Erratum. European Journal of Medicinal Chemistry. 124:1004-1005.
-
Carfilzomib triggers cell death in chronic lymphocytic leukemia by inducing proapoptotic and endoplasmic reticulum stress responses. Clinical Cancer Research. 22:4712-4726.
-
Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells. Experimental Hematology. 43:951-962.e3.
-
Combination of Pim kinase inhibitors and Bcl-2 antagonists in chronic lymphocytic leukemia cells. Leukemia and Lymphoma. 57:436-444.
-
Pim kinases in aml. 177-199.
-
Histological and Histochemical Studies on the Cotyledons of Some Legumes II. Reserve metabolites during seed development. Cytologia. 52:847-858.
-
BIOMASS ENERGY PRODUCTION FROM FOREST TREES BY TISSUE CULTURE. 69-99.
-
Does ATP promote or protect cells from apoptosis?. Cancer Biology and Therapy. 5:712.
-
Pharmacokinetic and pharmacodynamic evaluation of ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Drug Metabolism and Toxicology. 1-12.
-
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia. Leukemia and Lymphoma.
-
Idelalisib. Clinical Cancer Research. 21:1537-1542.
-
8-chloroadenosine sensitivity in renal cell carcinoma is associated with AMPK activation and mTOR pathway inhibition. PLoS One. 10.
-
Forodesine. Haematologica Meeting Reports. 3:70.
-
Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma. Expert Review of Hematology. 10:1-8.
-
Cellular pharmacodynamics as a guide to leukemia therapy. Cancer Bulletin. 46:8-14.
-
Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma. Oncotarget. 7:3461-3476.
-
Erratum. Future Oncology. 11:1584.
-
Mass propagation and genetic improvement of forest trees for biomass production by tissue culture. Biomass. 2:5-15.
-
Clofarabine. Pediatric Drugs. 7:265-266.
-
Idelalisib for the treatment of B-cell malignancies. Expert Opinion on Orphan Drugs. 3:109-123.
-
Prevention and treatment of cancer. Anticancer Research. 36:4971-4975.
-
Reactivation of smac-mediated apoptosis in chronic lymphocytic leukemia cells. Oncotarget. 7:39458-39472.
-
ACS Symposium Series. 639:265-278.
-
Elevated cyclin A associated kinase activity promotes sensitivity of metastatic human cancer cells to DNA antimetabolite drug. International Journal of Oncology. 47:782-790.
-
Forodesine - Preclinical studies. Haematologica Reports. 2:35-37.
-
Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells. European Journal of Medicinal Chemistry. 123:317-331.
-
Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia. Leukemia and Lymphoma. 1-11.
-
Decrease in total protein level of bruton's tyrosine kinase during ibrutinib therapy in chronic lymphocytic leukemia lymphocytes. Leukemia. 30:1803-1804.